Article

Effects of perfluorooctanoic acid on mouse mammary gland development and differentiation resulting from cross-foster and restricted gestational exposures.

U.S. EPA, ORD, National Health and Environmental Effects Research Laboratory, Research Triangle Park, NC, USA.
Reproductive Toxicology (Impact Factor: 3.14). 12/2008; 27(3-4):289-98. DOI: 10.1016/j.reprotox.2008.11.054
Source: PubMed

ABSTRACT The adverse consequences of developmental exposures to perfluorooctanoic acid (PFOA) are established in mice, and include impaired development of the mammary gland (MG). However, the relationships between timing or route of exposure, and consequences in the MG have not been characterized. To address the effects of these variables on the onset and persistence of MG effects in female offspring, timed pregnant CD-1 dams received PFOA by oral gavage over various gestational durations. Cross-fostering studies identified the 5mg/kg dose, under either lactational- or intrauterine-only exposures, to delay MG development as early as postnatal day (PND) 1, persisting beyond PND 63. Intrauterine exposure during the final days of pregnancy caused adverse MG developmental effects similar to that of extended gestational exposures. These studies confirm a window of MG sensitivity in late fetal and early neonatal life, and demonstrate developmental PFOA exposure results in early and persistent MG effects, suggesting permanent consequences.

0 Bookmarks
 · 
48 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The heritable component of breast cancer accounts for only a small proportion of total incidences. Environmental and lifestyle factors are therefore considered one of the major influencing components increasing breast cancer risk. Endocrine disrupting chemicals (EDCs) are ubiquitous in the environment. The estrogenic property of EDCs has thus seen many associations between ongoing exposures and the development of endocrine-related diseases, including breast cancer. The environment consists of a heterogenous population of EDCs and despite many identified modes of action, including that of altering the epigenome, drawing definitive correlations to breast cancer has been a point of much discussion. In this review we describe in detail well characterised EDCs and their actions in the environment; their ability to disrupt mammary gland formation in animal and human experimental models; and their associations with exposure and breast cancer risk. We also highlight the susceptibility of early-life exposure of each EDC to mediate epigenetic alterations, and where possible describe how these epigenome changes influence breast cancer risk.
    Endocrine Related Cancer 02/2014; · 5.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer risk has both heritable and environment/lifestyle components. The heritable component is a small contribution (5-27 %), leaving the majority of risk to environment (e.g., applied chemicals, food residues, occupational hazards, pharmaceuticals, stress) and lifestyle (e.g., physical activity, cosmetics, water source, alcohol, smoking). However, these factors are not well-defined, primarily due to the enormous number of factors to be considered. In both humans and rodent models, environmental factors that act as endocrine disrupting compounds (EDCs) have been shown to disrupt normal mammary development and lead to adverse lifelong consequences, especially when exposures occur during early life. EDCs can act directly or indirectly on mammary tissue to increase sensitivity to chemical carcinogens or enhance development of hyperplasia, beaded ducts, or tumors. Protective effects have also been reported. The mechanisms for these changes are not well understood. Environmental agents may also act as carcinogens in adult rodent models, directly causing or promoting tumor development, typically in more than one organ. Many of the environmental agents that act as EDCs and are known to affect the breast are discussed. Understanding the mechanism(s) of action for these compounds will be critical to prevent their effects on the breast in the future.
    Journal of Mammary Gland Biology and Neoplasia 03/2013; 18(1):43-61. · 7.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In order to compare between in vivo toxicity studies, dosimetry is needed to translate study-specific dose regimens into dose metrics such as tissue concentration. These tissue concentrations may then be compared with in vitro bioactivity assays to perhaps identify mechanisms relevant to the lowest observed effect level (LOEL) dose group and the onset of the observed in vivo toxicity. Here we examine the perfluorinated compounds (PFCs) perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS). We analyzed nine in vivo toxicity studies for PFOA and thirteen in vivo toxicity studies for PFOS. Both PFCs caused multiple effects in various test species, strains, and genders. We used a Bayesian pharmacokinetic (PK) modeling framework to incorporate data from six PFOA PK studies and two PFOS PK studies (conducted in three species) to predict dose metrics for the in vivo LOELs and no observed effect levels (NOELs). We estimated PK parameters for eleven combinations of chemical, species, strain, and gender. Despite divergent study designs and species-specific PK, for a given effect we found that the predicted dose metrics corresponding to the LOELs (and NOELs where available) occur at similar concentrations. In vitro assay results for PFOA and PFOS from EPA's ToxCast project were then examined. We found that most in vitro bioactivity occurs at concentrations lower than the predicted concentrations for the in vivo LOELs, and higher than the predicted concentrations for the in vivo NOELs (where available), for a variety of non-immunological effects. These results indicate that given sufficient PK data, the in vivo LOELs dose regimens, but not necessarily the effects, could have been predicted from in vitro studies for these two PFCs.
    Toxicological Sciences 09/2013; · 4.33 Impact Factor

Full-text (2 Sources)

View
6 Downloads
Available from
May 15, 2014